Key Highlights:
- Elephas Biosciences has entered an exclusive partnership with Neuberg Diagnostics to commercialize its elive live tissue platform in India, marking a key step in Elephas’ global expansion. Neuberg plans to launch its own clinical test using the platform by end-2026.
- The partnership combines Neuberg’s oncology and molecular diagnostics expertise with Elephas’ functional platform, which evaluates live tumor tissue to predict immunotherapy response. The approach aims to complement molecular profiling and give oncologists a broader view of which therapies may benefit individual patients.
- Neuberg will also serve as Elephas’ research partner in India, processing tumor biopsy samples on the elive platform at its flagship laboratory in Ahmedabad. The research is expected to generate local clinical evidence supporting the platform’s performance and broader adoption in Indian oncology care.
Implications:
The Elephas–Neuberg partnership brings a functional, live‑tissue test for immunotherapy response into India’s mainstream diagnostics, giving oncologists an additional tool alongside genetic profiling to better match patients to treatments and potentially reduce ineffective therapy cycles. By launching a local clinical test and generating Indian evidence, the deal can accelerate adoption of precision oncology in a large, growing cancer market while giving Elephas a scalable foothold in Asia that supports its broader global expansion strategy.
Source: PRnewswire
